More positive commercialisation news this morning from expert immunodiagnostics company Verici Dx (VRCI) regarding its pre-operation kidney transplant blood test Clarava.
The company said it will present a poster on the successful clinical validation study for Clarava at the American Society of Nephrology's annual conference, ASN Kidney Week, held from 2-5 November 2023 in Philadelphia:
"The poster will describe the design and positive results of Clarava's™ successful validation study, as previously announced, and is expected to help establish the product within the international nephrology community ahead of commercial launch.
Clarava™ is the only pre-transplant test of its kind currently available that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including increasing or decreasing adjustments in the type, dose, and duration of immunosuppressive agents." Verici explained in a statement.
Hopefully also laying the groundwork for 2024 to be a major break-through year for the group.
CEO Sara Barrington added: "ASN Kidney Week is an important platform for Verici Dx to raise awareness of its products including Clarava, being the largest international gathering attended by kidney health professionals and featuring the latest advances in treatment, research and cutting edge technology in the field of nephrology."
Time to be patient.
Follow News & Updates from Verici Dx: